title: [Efficacy of immunomodulators in children with respiratory diseases in environmentally poor areas].
abstract: The authors evaluated the clinical efficacy and safety of the antiviral and immunomodulatory drug Isoprinosine (inosine pranobex, Teva Pharmaceutical Industries, Ltd) in the treatment of bronchopulmonary diseases in children. One hundred and fifty-two children with acute respiratory diseases and an exacerbation of recurrent respiratory diseases were followed up. The use of Isoprinosine in their combined treatment showed both positive clinical changes and a better immunogram.
authors.forename: R Sh
authors.initials: RSh
authors.lastname: Iakupova
authors.forename: M A
authors.initials: MA
authors.lastname: Skachkova
authors.forename: S B
authors.initials: SB
authors.lastname: Choloian
authors.forename: E G
authors.initials: EG
authors.lastname: Karpova
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004781:Environmental Exposure / Q000009:adverse effects*; D018876:Environmental Illness / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D005500:Follow-Up Studies; D006801:Humans; D056747:Immunomodulation / Q000187:drug effects / Q000276:immunology*; D007542:Inosine Pranobex / Q000627:therapeutic use*; D009017:Morbidity / Q000639:trends; D012140:Respiratory Tract Diseases / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D012426:Russia / Q000453:epidemiology
chemical_list: D000276:Adjuvants, Immunologic; D007542:Inosine Pranobex